Prevalence and genotyping of Pneumocystis jirovecii in renal transplant recipients-preliminary report Author Szydłowicz, Magdalena Author Jakuszko, Katarzyna Author Szymczak, Anna Author Piesiak, Paweł Author Kowal, Aneta Author Kopacz, Żaneta Author Wesołowska, Maria Author Lobo, Maria Luísa Author Matos, Olga Author Hendrich, Andrzej B. Author Kicia, Marta text Parasitology Research 2019 181 2018-11-03 118 1 181 189 http://dx.doi.org/10.1007/s00436-018-6131-0 journal article 298235 10.1007/s00436-018-6131-0 2ef6c7d0-8965-433b-8b05-a9afefaf4f42 1432-1955 PMC6329730 30392033 11376753

Table 1 Comparison of Pneumocystis jirovecii -positive and Pneumocystis jirovecii - negative patients’ basic characteristics

	Pneumocystis jirovecii
Characteristic	Positive (n = 8)	Negative (n = 64)	P value
Age in years, mean (range)	55.1 (35–69)	52.2 (21–76)	0.292
Sex
Male	6 (75)	30 (46.9)	0.260
Female	2 (25)	34 (53.1)	0.260
Time after kidney transplantation in months, mean (range)	68.2 (4.7–142.5)	80 (0.16–225.6)	0.080
Kidney transplantation episode
First	7 (87.5)	54 (84.4)	1.000
Second	1 (12.5)	8 (12.5)	1.000
Third	–	2 (3.1)	1.000
Symptoms	3 (26.5)	17 (37.5)	0.676
Dyspnea	1 (12.5)	5 (7.8)	0.520
Fever	1 (12.5)	12 (18.75)	1.000
Unproductive cough	1 (12.5)	6 (9.4)	0.578
Ongoing prophylaxis	2 (25)	12 (18.75)	0.648
Immunosuppressive regimen
CI, prednisone, MMF	2 (25)	37 (57.8)	0.131
CI, prednisone, AZA	–	4 (6.2)	1.000
PSI, prednisone, MMF	–	1 (1.6)	1.000
PSI, prednisone	–	1 (1.6)	1.000
CI, prednisone	5 (62.5)	16 (25)	0.041*
CI, MMF	–	3 (4.7)	0.301
Prednisone	1 (12.5)	2 (3.1)	1.000
Other potential risk factors
CMV infection	1 (12.5)	10 (15.6)	1.000
Eosinophils/μl, mean (range)a	74 (0–250)	272 (0–7200)	0.040*
CRP mg/l, mean (range) b	32.1 (0.3–176.3)	42.3 (0.2–468)	0.144